Carna Biosciences, Inc.

As of June 30, 2026, Carna Biosciences, Inc. carries a market capitalization of 7.02B, placing it among publicly traded companies globally. Its enterprise value stands at 7.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Carna Biosciences, Inc.'s next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Carna Biosciences, Inc. has 20.64M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Carna Biosciences, Inc. maintains a current ratio of 12.08, meaning it holds 12.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Carna Biosciences, Inc.'s stock has gained approximately 67.45% over the past 52 weeks. The 50-day moving average sits at 397.98, while the 200-day moving average is 377.36.

As of June 30, 2026, Carna Biosciences, Inc. holds 1.10B in cash and equivalents against 1.99B in total debt, resulting in a net debt position of 865.15M. Total book value stands at -407.84M, with working capital of 1.56B providing operational flexibility.

Carna Biosciences, Inc.'s most recent stock split took place on December 26, 2013 with a 1:100 split ratio.